← Leaderboards
David W Goodrich
University Of Texas Md Anderson Can Ctr
$12,830,398
Attributed
$18,210,852
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,210,852 · 7
By mechanism
R01$10,441,529 · 4
U24$5,738,563 · 1
T32$1,630,052 · 1
R21$400,708 · 1
Top collaborators
- Leigh Ellis6 shared
- Song Liu6 shared
- Alan David Hutson5 shared
- Martin T Morgan3 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Scott M Lippman$54,535,308
- Russell D Klein$447,689
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseMalignant NeoplasmsResistanceMutationEpigenetic ProcessCellsMouse ModelCancer TherapyTherapy ResistantBaseTumor Suppressor GenesMalignant Neoplasm Of ProstateGeneticVariantRb1 GeneCancer CellMolecularCancer PatientDesignPublishingEngineeringNeurosecretory SystemsIn VivoProstate Adenocarcinoma
Grant awards (49)
Coordinating and Data Management Center for Acquired Resistance to Therapy Network$1,832,533
U24 · FY2025 · CA
Coordinating and Data Management Center for Acquired Resistance to Therapy Network$986,818
U24 · FY2024 · CA
Coordinating and Data Management Center for Acquired Resistance to Therapy Network$758,183
U24 · FY2024 · CA
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer$382,429
R01 · FY2024 · CA · contact PI
Coordinating and Data Management Center for Acquired Resistance to Therapy Network$1,024,775
U24 · FY2023 · CA
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer$629,075
R01 · FY2023 · CA · contact PI
YAP1 and RB1 cooperate to regulate lung cancer lineage plasticity and therapeutic resistance$85,850
U24 · FY2023 · CA · contact PI
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer$8,020
R01 · FY2023 · CA · contact PI
Coordinating and Data Management Center for Acquired Resistance to Therapy Network$1,050,404
U24 · FY2022 · CA
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer$109,257
R01 · FY2022 · CA · contact PI
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer$55,630
R01 · FY2022 · CA · contact PI
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer$577,631
R01 · FY2021 · CA · contact PI
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer$48,583
R01 · FY2021 · CA · contact PI
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer$577,631
R01 · FY2020 · CA · contact PI
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$505,760
R01 · FY2020 · CA · contact PI
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer$614,981
R01 · FY2019 · CA · contact PI
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$490,587
R01 · FY2019 · CA · contact PI
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$505,760
R01 · FY2018 · CA · contact PI
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$250,000
R01 · FY2018 · CA · contact PI
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$505,760
R01 · FY2017 · CA · contact PI
Exploiting RB1 deficiency for the treatment of lethal neuroendocrine prostate cancer$505,760
R01 · FY2016 · CA · contact PI
(PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypes$179,119
R21 · FY2014 · CA · contact PI
(PQB5) Does the timing of Pten and Rb1 mutation affect prostate cancer phenotypes$221,589
R21 · FY2013 · CA · contact PI
Drug Development and Cancer Treatments$144,916
T32 · FY2012 · CA · contact PI
The Role of Thoc1 in Normal Development and Cancer$362,009
R01 · FY2011 · CA · contact PI
Drug Development and Cancer Treatments$168,750
T32 · FY2011 · CA · contact PI
Requirements for Normal Rb Function In Vivo$376,377
R01 · FY2010 · CA · contact PI
The Role of Thoc1 in Normal Development and Cancer$367,869
R01 · FY2010 · CA · contact PI
Drug Development and Cancer Treatments$140,315
T32 · FY2010 · CA · contact PI
Requirements for Normal Rb Function In Vivo$383,842
R01 · FY2009 · CA · contact PI
The Role of Thoc1 in Normal Development and Cancer$362,688
R01 · FY2009 · CA · contact PI
Drug Development and Cancer Treatments$151,417
T32 · FY2009 · CA · contact PI
The Role of Thoc1 in Normal Development and Cancer$357,658
R01 · FY2008 · CA · contact PI
Drug Development and Cancer Treatments$175,868
T32 · FY2008 · CA · contact PI
The Role of Thoc1 in Normal Development and Cancer$339,144
R01 · FY2007 · CA · contact PI
Drug Development and Cancer Treatments$108,516
T32 · FY2007 · CA · contact PI
Requirements for Normal Rb Function In Vivo$476,566
R01 · FY2006 · CA · contact PI
Drug Development and Cancer Treatments$167,414
T32 · FY2006 · CA · contact PI
Requirements for Normal Rb Function In Vivo$481,348
R01 · FY2005 · CA
Drug Development and Cancer Treatments$178,280
T32 · FY2005 · CA
Drug Development and Cancer Treatments$33,001
T32 · FY2005 · CA
Requirements for Normal Rb Function In Vivo$315,592
R01 · FY2004 · CA
DRUG DEVELOPMENT AND CANCER TREATMENTS$149,873
T32 · FY2004 · CA
DRUG DEVELOPMENT AND CANCER TREATMENTS$32,406
T32 · FY2004 · CA
Requirements for Normal Rb Function In Vivo$311,876
R01 · FY2003 · CA
DRUG DEVELOPMENT AND CANCER TREATMENTS$147,543
T32 · FY2003 · CA
DRUG DEVELOPMENT AND CANCER TREATMENTS$31,753
T32 · FY2003 · CA
Requirements for Normal Rb Function In Vivo$308,268
R01 · FY2002 · CA
REGULATION OF RB PROTEIN FUNCTION BY CYCLIN-DEPENDENT$231,428
R01 · FY2000 · CA